Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy
- PMID: 20446847
- PMCID: PMC2873127
- DOI: 10.1086/652750
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy
Abstract
Background: To identify inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency virus (HIV) disease, we explored associations between AIDS or death and different inflammatory markers, including selected soluble tumor necrosis factor superfamily receptors (sTNFRs) and ligands, interleukin (IL)-6, and CD8 T cell activation, in individuals treated with highly active antiretroviral therapy (HAART).
Methods: A case-control study of subjects in AIDS Clinical Trials Group (ACTG) protocols 384 and 5015, who were matched according to the CD4 cell count and plasma viral load at baseline, was performed using conditional logistic regression.
Results: Higher pretreatment concentrations of sTNFR-1, sCD27, sCD40L, and plasma IL-6 were associated with a new AIDS-defining illness or death in separate models adjusted for age, sex, hemoglobin, and the latest CD4 cell counts. In additional models that excluded case patients with opportunistic infections, sTNFR-1, sCD27, and sCD40L were each associated with a new AIDS-defining malignancy or death that developed at a median of 51 weeks after initiation of HAART, by which time the majority of subjects had a CD4 cell count of >200 cells/cm(3) and had achieved a plasma viral load of <50 copies/mL.
Conclusion: These data are compatible with a model in which these soluble inflammatory markers identify pathways that may contribute to the pathogenesis of HIV disease progression, pathways that might not be a direct consequence of ongoing HIV type 1 replication.
Conflict of interest statement
Conflicts of Interest:
R.T.G. received grant funding from Tibotec and Gilead and an honorarium from GlaxoSmith Kline.
R.B.P. is on the Speaker’s bureau for Bristol Meyers Squibb and Gilead.
G.K.R. received grant funding from Gilead, Schering-Plough, and consulting fees from Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals and Tibotec.
A.L. received honoraria from Abbott Laboratories and Bristol-Myers Squibb.
Figures


Comment in
-
Inflammation and complications of HIV disease.J Infect Dis. 2010 Jun 15;201(12):1783-5. doi: 10.1086/652751. J Infect Dis. 2010. PMID: 20446849 No abstract available.
Similar articles
-
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.J Infect Dis. 2014 Oct 15;210(8):1248-59. doi: 10.1093/infdis/jiu254. Epub 2014 May 1. J Infect Dis. 2014. PMID: 24795473 Free PMC article.
-
Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x. Scand J Immunol. 2008. PMID: 19055701
-
Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression.J Infect Dis. 2009 Jun 15;199(12):1872-82. doi: 10.1086/598858. J Infect Dis. 2009. PMID: 19432535 Free PMC article.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Enferm Infecc Microbiol Clin. 2011. PMID: 21388714 Spanish.
Cited by
-
HIV and inflammation: mechanisms and consequences.Curr HIV/AIDS Rep. 2012 Jun;9(2):139-47. doi: 10.1007/s11904-012-0118-8. Curr HIV/AIDS Rep. 2012. PMID: 22528766 Review.
-
Cannabinoids: Therapeutic Use in Clinical Practice.Int J Mol Sci. 2022 Mar 19;23(6):3344. doi: 10.3390/ijms23063344. Int J Mol Sci. 2022. PMID: 35328765 Free PMC article. Review.
-
Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793. BMJ Open. 2019. PMID: 30659041 Free PMC article.
-
Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.J Nutr Biochem. 2018 Nov;61:1-16. doi: 10.1016/j.jnutbio.2018.04.004. Epub 2018 Apr 19. J Nutr Biochem. 2018. PMID: 29886183 Free PMC article. Review.
-
The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.Trials. 2014 Oct 7;15:390. doi: 10.1186/1745-6215-15-390. Trials. 2014. PMID: 25293882 Free PMC article. Clinical Trial.
References
-
- Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231–41. - PubMed
-
- Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis. 2005;191:694–701. - PubMed
-
- Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 −1082G allele in a Zimbabwean cohort of HIV-1-infected adults. Aids. 2007;21:2283–91. - PubMed
-
- Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346–55. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI69501/AI/NIAID NIH HHS/United States
- K01 AI062435/AI/NIAID NIH HHS/United States
- R01 AI066992/AI/NIAID NIH HHS/United States
- AI 36219/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- AI062435/AI/NIAID NIH HHS/United States
- M01 RR000080/RR/NCRR NIH HHS/United States
- P30 AI036219/AI/NIAID NIH HHS/United States
- UM1 AI069472/AI/NIAID NIH HHS/United States
- 5 RO1 AI066992-04/AI/NIAID NIH HHS/United States
- UM1 AI069501/AI/NIAID NIH HHS/United States
- AI U01 68635/AI/NIAID NIH HHS/United States
- U01 AI069501/AI/NIAID NIH HHS/United States
- AI069472/AI/NIAID NIH HHS/United States
- AI 68636/AI/NIAID NIH HHS/United States
- U01 AI069472/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials